Form 483

Gland Pharma Limited Form 483, 2019-05-16

FDA issued a Form 483 to Gland Pharma Limited on 2019-05-16 with 7 public-safe observations.

483· Form 483 issuedHuman Drugs7 observations

Gland Pharma Limited · Hyderabad, India · Issued May 16, 2019

Overview

  • 7 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

16 May 2019
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Michael A Charles

16 May 2019
21 CFR 211.192

Written record of investigation incomplete

Cited by Michael A Charles

16 May 2019
21 CFR 211.42(b)

Product flow through building is inadequate

Cited by Michael A Charles

16 May 2019
21 CFR 211.42(c)(10)(iv)

Environmental Monitoring System

Cited by Michael A Charles

16 May 2019
21 CFR 211.56(c)

Written procedures lacking for use of pesticides etc.

Cited by Michael A Charles

Inspected site

GPGland Pharma LimitedHyderabad, India

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.42(b)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations1x
21 CFR 211.56(c)Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)(2)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 7 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere